Clinical Trial Update: VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing VentaProst to conventionally-administered aerosolized epoprostenol in patients with pulmonary hypertension undergoing cardiac surgery …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Epoprostenol (aerosolized) (epoprostenol)
• VentaProst

Snippet

Sponsor: Aerogen Pharma Limited | Conditions: Pulmonary Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2025-07-31